Monteverde ML

Language: Spanish
References: 10
Page: 197-198
PDF size: 127.50 Kb.

Text Extraction

No abstract.

REFERENCES

1. Dwyer ME, Krambeck AE, Bergstralh EJ, MillinerDS, Lieske JC, Rule AD. Temporal trends in incidenceof kidney stones among children: a 1316 V. O.Edvardsson and D. J. Sas 25-year population-basedstudy. J Urol. 2012;188:247–252.

2. Penido MG, Srivastava T, Alon US. Pediatric primaryurolithiasis: 12-year experience at a MidwesternChildren’s Hospital. J Urol. 2013; 189:1493-1497.

3. Cochat P, Rumsby G : Primary Hyperoxaluria. N EnglJ Med 2013;369:649-658.

4. Ermer T, Nazzal L, Tio MC, Waikar S, AronsonPS, Knauf F. Oxalate homeostasis. Nat Rev Nephrol.2023;2:123-138.

5. Groothoff JW, Metry E, Deesker L, Garrelfs S,Acquaviva C, Almardini R, Beck BB, Boyer O,Cerkauskiene R, Ferraro PM, Groen LA, Gupta A,Knebelmann B, Mandrile G, Moochhala SS, PrytulaA, Putnik J, Rumsby G, Soliman NA, Somani B,Bacchetta J. Clinical practice recommendations forprimary hyperoxaluria: an expert consensus statementfrom ERKNet and OxalEurope. Nat Rev Nephrol.2023 Mar; 3:194-211.

6. Ministerio de Salud de la Nación. Listado deenfermedades poco frecuentes en Argentina. Published2022. Accessed June 27, 2022. https://www.argentina.gob.ar/salud/pocofrecuentes/listado

7. FDA News Release: FDA Approves First Drug to TreatRare Metabolic Disorder [Link] https://www.fda.gov/news-events/press-announcements/ FDA ApprovesFirst Drug to Treat Rare Metabolic Disorder | FDA

8. EMA Summary of Product Characteristics: Oxlumo(Lumasiran) Subcutaneous Injection [Link]. EuropeanMedicine Agency (EMA). Lumasiran. Published 2020.Accessed June 28, 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo

9. Alylam Pharmaceuticals: Lumasiran ClinicalDevelopment Program [Link] Lumasiran-ILLUMINATE-Fact-Sheet.pdf (alnylam.com)

10. Lumasiran para hiperoxaluria primaria tipo 1. Grupode Trabajo. Disponible en: informe-evaluacionultrarrapido-6-lumasiran.pdf (argentina.gob.ar)